Whole-body magnetic resonance imaging (MRI) may serve as a valuable noninvasive tool for assessing the risk of heart attack and stroke in diabetic patients, according to a new clinical study published online in the journal Radiology. 

Sunshine Heart Inc. has launched a website dedicated to providing information to patients suffering from moderate to severe heart failure to learn about its C-Pulse U.S. pivotal trial, COUNTER HF(TM).

Medtronic Inc. announced clinical trial results showing that heart failure patients treated with its AdaptivCRT feature experienced a nearly 50 percent reduction in atrial fibrillation (AF) risk. Pioneered by Medtronic, the AdaptivCRT technology is a feature on certain cardiac resynchronization therapy-defibrillators (CRT-Ds) that continually adjusts therapy to a patient's natural heart rhythms and minimizes the amount of unnecessary right ventricular (RV) pacing. The results were presented as a late breaking clinical trial at the Heart Failure Society of America's 17th Annual Scientific Meeting.

At RSNA 2013, GE Healthcare will highlight the latest hardware and advanced applications for its Discovery IGS angiography platform. These updates are geared towards addressing the challenges of healthcare providers, support clinical decision making and helping clinicians in refining overall patient care.

Critical Diagnostics announced the clinical study, “Head-to-head comparison of two myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 vs. Galectin-3,” recently published online in Journal of the American College of Cardiology (JACC) comparing the company’s cardiac biomarker ST2 to Galectin-3 (Gal-3), a biomarker from BG Medicine, found ST2 to be superior.

Ascendian Healthcare Consulting announced a new service line to assist clients with ensuring the confidentiality, integrity and availability of patient data — the medical imaging client’s privacy, data security and patient safety consulting services.

A study by Cutting Edge Information found that pharmaceutical companies measure cost per patient per month to allow trials of different sizes and durations to be compared easily. This measurement also helps to illustrate the high costs associated with delays.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now